Copyright © 2004 by the European Society of Cardiology.
Clinical research
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study
a University of Florence, Italy
b University of Bologna, Italy: Hospital St. Orsola, Paol. 24 40138, Bologna
c University of Milan, Italy
d University "La Sapienza", Rome, Italy
Received February 19, 2004; revised June 10, 2004; accepted July 1, 2004 * Corresponding author. Tel./fax: +39 51 6364668 (E-mail: trombosi{at}orsola-malpighi.med.unibo.it).
See page 1769 for the editorial comment on this article (doi:10.1016/j.ehj.2004.08.008)
Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD).
Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lower amongst patients who received picotamide (3.0%) than in those who received aspirin (5.5%) with a relative risk ratio for picotamide versus aspirin of 0.55 (95% CI: 0.31–0.98%). Events were reported in 43 patients (7.1%) on picotamide and 53 (8.7%) on aspirin. The combined endpoint of mortality and morbidity had a slightly lower incidence in the picotamide group but this difference did not reach statistical significance.
Conclusion Picotamide is significantly more effective than aspirin in reducing overall mortality in type 2 diabetic patients with associated PAD.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?
- Paolo Gresele and Rino Migliacci
EHJ 2004 25: 1769-1771.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. S. Berger, M. J. Krantz, J. M. Kittelson, and W. R. Hiatt Aspirin for the Prevention of Cardiovascular Events in Patients With Peripheral Artery Disease: A Meta-analysis of Randomized Trials JAMA, May 13, 2009; 301(18): 1909 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Angiolillo Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions Diabetes Care, April 1, 2009; 32(4): 531 - 540. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sobel and R. Verhaeghe Antithrombotic Therapy for Peripheral Artery Occlusive Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 815S - 843S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Outlook Commentaries Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2007; 19(1): 87 - 99. [Abstract] [PDF]
|
|
|
|
 |
|
 D. G Hackam and J. W Eikelboom Antithrombotic treatment for peripheral arterial disease Heart, March 1, 2007; 93(3): 303 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Hackam Medical management of peripheral arterial disease. JAMA, July 5, 2006; 296(1): 41 - 41. [Full Text] [PDF]
|
|
|
|
|
|
J. Eikelboom, G. Hankey, and P. Norman Medical Management of Peripheral Arterial Disease--Reply JAMA, July 5, 2006; 296(1): 41 - 42. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Buccellati, A. Sala, G. Rossoni, V. Capra, G. E. Rovati, A. Di Gennaro, G. Folco, S. Colli, and C. Casagrande Pharmacological Characterization of 2NTX-99 [4-Methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a Potential Antiatherothrombotic Agent with Antithromboxane and Nitric Oxide Donor Activity in Platelet and Vascular Preparations J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 830 - 837. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R Hiatt and M. J Krantz Masterclass series in peripheral arterial disease: Antiplatelet therapy for peripheral arterial disease and claudication Vascular Medicine, February 1, 2006; 11(1): 55 - 60. [Abstract] [PDF]
|
|
|
|
 |
|
 D. A Smith Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Evid. Based Med., June 1, 2005; 10(3): 79 - 79. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gresele and R. Migliacci Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur. Heart J., October 2, 2004; 25(20): 1769 - 1771. [Full Text] [PDF]
|
|